読み込み中
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
通常取引
$4.88
−$0.10 · -2.01%
日中の時刻はETです。市場データは遅延する場合があります。
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
日中レンジ
現在 $4.88
52週レンジ
現在 $4.88
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
65
割安
センチメント
40
弱気
リスク
62
高リスク
モメンタム
32
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
日中レンジ
現在 $4.88
52週レンジ
現在 $4.88
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 5942.5万 USD | 5694.4万 USD | 5015.5万 USD | 5387万 USD | 4910.9万 USD |
| 売上原価 | 3090万 USD | 2838.9万 USD | 2940.1万 USD | 2953.2万 USD | 2363.2万 USD |
| 粗利益 | 2852.5万 USD | 2855.5万 USD | 2075.4万 USD | 2433.8万 USD | 2547.7万 USD |
| 研究開発 | 908.4万 USD | 682.5万 USD | 954.4万 USD | 1154.5万 USD | 937.4万 USD |
| 販売・一般管理 | 2047万 USD | 1688.4万 USD | 1813.1万 USD | 1724.2万 USD | 1549.6万 USD |
| 営業費用 | 2966.5万 USD | 2370.9万 USD | 2767.5万 USD | 2878.7万 USD | 2487万 USD |
| 減価償却費と償却費 | 137.7万 USD | 164万 USD | 186.7万 USD | 224.6万 USD | 162.7万 USD |
| 営業利益 | −114万 USD | 484.6万 USD | −692.1万 USD | −444.9万 USD | 60.7万 USD |
| 純利益 | −117.5万 USD | 470.1万 USD | −727.6万 USD | −533.5万 USD | 54.8万 USD |
会社概要が更新されました 2026年10月9日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$12.00
上昇余地（145.90%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2015年8月12日 | 1:12 | — | — |
発効済み 2015年8月12日
1:12
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
